Financing will accelerate commercialization of BioTrove’s micro- and nano-scale technology platforms

Woburn, MA, April 26, 2004—BioTrove, Inc., a biotechnology company developing and commercializing nano-fluidic systems for the life sciences, today announced the appointment of Alan B. Carter as Vice President, Worldwide Sales. Mr. Carter has 20 years of experience in analytical and biotechnology instrumentation, including 10 years of experience in the field of genetic and protein analysis. Most recently, Mr. Carter served as the Executive Director of Business Development at GeneLogic (NASDAQ: GLGC).

“Alan brings a tremendous depth of experience in sales and knowledge of the life science marketplace,” said Patrick T. Carroll, Chief Business Officer for BioTrove. “His vast experience will play a major role as we begin to present our Living Chip™ platform and Momentum™ Assay Development and Screening technologies to customers, as well as begin to seek beta sites for products to be released later this calendar year.” Mr. Carroll also noted that BioTrove plans to launch its first product from the Living Chip platform in the coming months. The company recently introduced its Momentum screening service, which unlocks the value of intractable drug targets.

“I am extremely pleased to have Alan join us as the latest member of BioTrove’s experienced executive team,” said Robert Ellis, President and Chief Executive Officer. “This team, along with the recent progress made in our platforms, enables us to readily pursue our commercialization efforts.”

Prior to joining BioTrove, Mr. Carter was responsible for developing GeneLogic’s pharmaceutical revenue as their Executive Director of Business Development. Before this, he served as Sales Director of Pharmaceutical Accounts for Celera Genomics, which he joined after serving as Vice President of Sales and Marketing for Lark Technologies. Mr. Carter began his experience in the field of genetic and protein analysis with Applied Biosystems where he served as Western Regional Manager. Prior to Applied Biosystems, Mr. Carter was a Western Regional Manager with Polygen Corporation and a sales representative with Perkin Elmer Corporation. He holds a B.S. degree in Chemistry from Virginia Tech.

About the Living Chip™
The Living Chip™ is a broadly applicable nano-liter fluidics technology platform for massively parallel and low-volume analysis of genetic, genomic, proteomic, biochemical and cellular samples. The platform uniquely combines the parallelism of microarrays with the data quality and sensitivity of PCR to perform genetic and genomic assays, including genotyping and RNA expression analysis.

About Momentum™ Assay Development and Screening
Momentum Assay Development and Screening is a patent-protected, ultra high-throughput mass spectrometry service that enables microliter-scale functional assay development and screening of challenging targets with promising biology that are generally not pursued. In the interest of accelerating discovery, companies often choose to forego many highly promising targets, because of the complexity in developing screening assays around such targets. Momentum dissolves this bottleneck, transforming the drug discovery process by providing assay development and screening for these targets.

About BioTrove, Inc.
BioTrove, Inc. is a biotechnology company focused on advancing life science and drug discovery research by leveraging revolutionary micro- and nano-scale technologies. BioTrove has two core platforms: the Living Chip™, a broadly applicable nano-liter fluidics technology platform for massively parallel and low-volume analysis of genetic, genomic, proteomic, biochemical and cellular samples and Momentum™ Assay Development and Screening, an assay development and high throughput screening service that unlocks the value of intractable drug targets.

For more information contact:

Patrick T. Carroll
BioTrove, Inc.
info@biotrove.com
(781) 721-3632

Barbara Askjaer
Feinstein Kean Healthcare
Barbara.Askjaer@fkhealth.com
(617) 761-6759